雷珠单抗联合微脉冲激光治疗中心性浆液性脉络膜视网膜病变患者黄斑形态变化
Study on the changes of morphotogic macular of ranibizumab combined with micropulse laser in the treatment of central serous chorioretinopathy
郭艳1
作者信息
- 1. 焦作煤业集团有限责任公司中央医院眼科,焦作 454150
- 折叠
摘要
目的 分析雷珠单抗联合微脉冲激光对中心性浆液性脉络膜视网膜病变(CSC)患者的黄斑形态影响.方法 回顾性病例对照研究.选择焦作煤业集团中央医院2021年5月至2023年5月120例(120眼)CSC进行研究.根据治疗方法的不同将其分为两组,每组各60例,对照组进行微脉冲激光光凝治疗,观察组在对照组基础上增加雷珠单抗玻璃体内注射治疗.比较两组临床疗效,包括最佳矫正视力(BCVA,logMAR)、黄斑中心区厚度(CMT)、黄斑下积液率、神经上皮层水肿率及血液流变学指标资料.结果 观察组有效率为95.00％(57/60),高于对照组的80.00％(48/60),差异有统计学意义(x2=6.17,P=0.013).观察组治疗后BCVA(0.53±0.06)优于对照组(0.70±0.11)(t=9.30,P＜0.001),观察组治疗后 CMT(241.16±20.61)µm 低于对照组(300.84±26.84)μm(t=13.66,P＜0.001).观察组黄斑下积液率为1.67％(1/60),低于对照组的11.67％(7/60),差异有统计学意义(x2=4.82,P=0.028);神经上皮层水肿率为3.33％(2/60),低于对照组的16.67％(10/60),差异有统计学意义(x2=5.93,P=0.015).观察组与对照组治疗后红细胞数量(RBC)[(3.26±0.26)× 1012/Lvs(4.46±0.85)×1012/L,t=10.46,P＜0.001],血浆黏度(PV)[(1.01±0.11)mPa·s vs(1.45± 0.15)mPa·s,t=18.32,P＜0.001],全血黏度(WBV)[(4.01±0.34)mPa·s vs(5.46±1.13)mPa·s,t=9.52,P＜0.001]差异均有统计学意义.结论 雷珠单抗联合微脉冲激光可有效改善CSC患者视力,降低其CMT,改善其眼底血液循环,减轻其对黄斑形态的影响.
Abstract
Objective To analyze the effects of ranibizumab combined with micropulse laser on macular morphology in patients with central serous chorioretinopathy(CSC).Methods This was a retrospective case-control study.A total of 120 eyes of 120 patients with CSC from May 2021 to May 2023 in the Central Hospital of Jiaozuo Coal Industry Group were selected.Based on different treatment methods,the patients were divided into two groups,with 60 cases in each group.The control group received micropulse laser photocoagulation,and the observation group was treated with ranibizumab on the basis of the control group.The clinical efficacy between the two groups was compared,in cluding best corrected visual acuity(BCVA,logMAR),central macular thickness(CMT),submacular fluid accumulation rate,neurocortical edema rate and hemorheological blood indexes.Results The effective rate of the observation group was 95.00％(57/60),which was higher than that of the control group[80.00％(48/60)],and the difference was statistically significant(x2=6.17,P=0.013).BCVA(0.53±0.06)in the observation group was better than that in the control group(0.70±0.11)(t=9.30,P＜0.001).CMT of the observation group[(241.16± 20.61)µm]was lower than that of the control group[(300.84±26.84)pm]after treatment(t=13.66,P＜0.001).The rate of submacular fluid accumulation in the observation group was 1.67％(1/60),which was lower than that in the control group[11.67％(7/60)],and the difference was statistically significant(x2=4.82,P=0.028).The neurocortical edema rate was 3.33％(2/60),which was lower than the 16.67％(10/60)in the control group,and the difference was statistically significant(x2=5.93,P=0.015).The number of red blood cells(RBC)after treatment in the observation group[(3.26±0.26)×1012/L]were lower than the(4.46±0.85)× 1012/L in the control group(t=10.46,P＜0.001).Plasma viscosity(PV)was lower than that in the control group[(1.01±0.11)mPa·s vs(1.45±0.15)mPa·s,t=18.32,P＜0.001].The differences were all statistically significant.Whole blood viscosity(WBV)in the observation group was lower than that in the control group[(4.01±0.34)mPa·s vs(5.46±1.13)mPa·s,t=9.52,P＜0.001].Conclusion Ranibizumab combined with micropulse laser can effectively improve the visual acuity of patients with CSC,reduce their CMT,improve their fundus blood circulation and reduce their influence on macular morphology.
关键词
中心性浆液性脉络膜视网膜病变/雷珠单抗/微脉冲激光/黄斑形态Key words
Central serous chorioretinopathy/Ranibizumab/Micropulse laser/Macular morphology引用本文复制引用
出版年
2024
NETL
NSTL
万方数据